新炬網絡(605398.SH)擬以募集資金向新炬技術增資實施募投項目
格隆匯3月11日丨新炬網絡(605398.SH)公佈,募投項目“大數據日誌分析管理平台升級項目”和“數據治理及資產管理平台升級項目”的實施主體為新炬技術。公司結合募集資金實際到賬情況及公司未來發展規劃,為提高募集資金使用效率,加快推進募投項目的建設進度,公司以向募投項目實施主體新炬技術增資的方式實施募投項目,增資資金用於相關項目的投入,不得用作其他用途。
公司使用募集資金向新炬技術增資6394.43萬元,其中2900.00萬元計入新增註冊資本,剩餘3494.43萬元計入資本公積。增資完成後,新炬技術註冊資本由5100.00萬元增加至8000.00萬元,仍為公司的全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.